Related Experiment Videos
Recombinant activated factor VII for bleeding in patients without inherited bleeding disorders
Issues in Emerging Health Technologies
|April 11, 2006
Summary
Recombinant activated factor VII (rFVIIa) shows potential for non-hemophilic bleeding control, with some trials indicating reduced mortality in intracerebral hemorrhage and fewer transfusions in trauma patients.
Area of Science:
- Pharmacology
- Hematology
- Critical Care Medicine
Background:
- Recombinant activated factor VII (rFVIIa) is approved for hemophilia but increasingly used off-label.
- Off-label uses include surgical bleeding, severe trauma, and intracerebral hemorrhage (ICH).
Purpose of the Study:
- To evaluate the efficacy and safety of rFVIIa in non-hemophilic patients.
- To assess the potential of rFVIIa for indications beyond inherited bleeding disorders.
Main Methods:
- Review of clinical trials investigating rFVIIa in non-hemophilic patients.
- Analysis of outcomes including mortality and blood transfusion requirements.
Main Results:
- One trial showed reduced mortality in ICH patients treated with rFVIIa.
- Another trial indicated fewer massive blood transfusions in trauma patients, without significant mortality difference.
- Ongoing Phase III trials in ICH and trauma aim to further clarify efficacy.
Conclusions:
- rFVIIa demonstrates potential for non-hemophilic bleeding management.
- Further research, including adequately powered randomized controlled trials, is necessary to establish efficacy and safety for new indications.
- Cost-effectiveness and clinical efficacy must be proven for wider non-hemophilic adoption.